Andrea Lobo,  —

The Parkinson’s Foundation is investing $2.8 million in 30 research grants to help advance potential new therapies for Parkinson’s disease. The focus is to accelerate pioneering research into several aspects of the disease, conducted by early career researchers or those more established. The ultimate goal is to find…

Gcanrx soon will open a Phase 2 clinical trial of a neuroprotective cannabinoid treatment that the company expects could benefit people with a range of neurological conditions, including Parkinson’s disease. The safety and efficacy trial, approved to take place in Israel, is expected to begin enrolling children with…

The early appearance of minor hallucinations in people with Parkinson’s disease might be a predictor of faster cognitive decline, a recent study suggests. Among those with hallucinations, cognitive decline was also associated with electrical activity in the frontal lobe, a part of the brain that controls cognition. The study,…

Treatment with bemdaneprocel (BRT-DA01), BlueRock Therapeutics’s investigational cell-based therapy, was safe and well tolerated among patients with advanced-stage Parkinson’s disease, according to top-line results from a Phase 1 clinical trial. Furthermore, data also showed that transplantation was feasible, and there was evidence of cell survival and engraftment in…

The Parkinson’s Foundation has expanded its Global Care Network by adding four Centers of Excellence and four Comprehensive Care Centers to increase access to specialized multidisciplinary care for people with Parkinson’s disease. This expansion recognizes centers within a broad geographic region, including the first-ever designations in Wisconsin,…

Freeline Therapeutics announced plans to leverage knowledge gained from its FLT201 gene therapy program in Gaucher disease to advance a similar candidate to treat people whose Parkinson’s is tied to mutations in the GBA1 gene. “Our GBA1-linked Parkinson’s disease program is a natural extension of our…

Following a positive safety review, Annovis Bio‘s Phase 3 clinical trial testing oral buntanetap for the treatment of early-stage Parkinson’s disease can move forward as originally designed, the company announced. That positive review came from the Data and Safety Monitoring Board (DSMB), an independent group of experts, which…

Koneksa has partnered with Beacon Biosignals to launch a clinical trial focused on advancing research in neuroscience, including Parkinson’s disease, with an aim to develop electroencephalogram (EEG) biomarkers. EEG technology has long been used to measure the brain’s electrical activity and identify evidence of neurological disorders like…

Enrollment is now complete for a Phase 3 trial of buntanetap, an oral therapy candidate from Annovis Bio that aims to improve cognitive and motor skills in early-stage Parkinson’s disease, the company has announced. Since the first participant was dosed in August 2022, more than 640 patients…

Components from tire wear, higher temperatures and age accelerate the degeneration of dopaminergic neurons in Parkinson’s disease, a new study done in nematode worms suggests. The study, “Tire components, age and temperature accelerate neurodegeneration in C. elegans models of Alzheimer’s and Parkinson’s disease,” was published in the journal…